Wegovy® providers &
prescriptions in Baton Rouge, LA
Verified Wegovy providers in Baton Rouge, LA. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]
Find an Wegovy provider in Louisiana.
Every entry is checked against the NPI registry and the Louisiana medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.
How to get Wegovy in Baton Rouge.
35 GLP-1 prescribers and 7 local resource types are on record for Baton Rouge, plus 2 nearby towns in the directory.
Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Louisiana’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.
An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.
Wegovy is the brand name for semaglutide at the higher 2.4 mg dose. It is the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]
In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9%, roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]
Community health · CDC
Weight & metabolic health in Louisiana
Diagnosed diabetes reaches 14.6% of adults in Louisiana.
- of Louisiana adults have obesity
- 39.2%
- diagnosed diabetes
- 14.6%
Age-adjusted estimates for Louisiana, community figures, not individual risk. CDC BRFSS 2024.
The prescription is one part. Here is the rest, in Baton Rouge.
Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Baton Rouge, LA, ordered as the registry lists them, never by who pays us.
Registered dietitians
A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.
10202 Perkins Rowe Apt 2001
7801 Scenic Highway
Nutritionists
A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.
3838 N Causeway Blvd
628 N 4Th St # 4
6419 Tiger Pointe Dr
2754 Brandywine Dr
What the trials actually showed.
We summarize results from the STEP program, the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication, and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.
Most side effects are gastrointestinal and resolve within weeks.
The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]
Most directories hide the price. We don't.
Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.
Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.
NPI-verified Wegovy (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.
Find NPI-verified Wegovy (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.
The questions people ask before they book.
Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.
FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]